Skip to content
Live From WCLC 2024: Meeting Summary episode artwork

Sep 11, 2024 40 min

Live From WCLC 2024: Meeting Summary

from Lung Cancer Considered Hosted by IASLC

In this special WCLC 2024 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap the conference and discuss the meeting's most impactful research. Dr. Jacob Sands discusses overall survival updates from TROPION-Lung01 with datopotamab deruxtecan and DeLLphi-301 with tarlatamab. Dr. Hidehito Horinouchi reports results from the LUMINOSITY study of telisotuzumab vedotin, and Dr. Noemi Reguart gives some perspective on TRUST-II with talectrectinib. The group discusses the biggest stories from WCLC 2024, their favorite moments, and a preview of WCLC 2025 in Barcelona, Spain. Guests: Dr. Hidehito Horinouchi Assistant Chief, Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo General Secretary, Japan Clinical Oncology Group Dr. Noemi Reguart Clinical Professor at the University of Barcelona Coordinator of the Thoracic Oncology Unit, Hospital Clínic Barcelona, Spain WCLC 2025 Co-Chair Dr. Jacob Sands Assistant Professor of Medicine, Harvard Medical School Lowe Cancer Center for Thoracic Oncology Dana Farber Cancer Institute

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Live From WCLC 2024: Meeting Summary

0:00 40:33

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Lung Cancer Considered?

This episode is 40 minutes long.

When was this Lung Cancer Considered episode published?

This episode was published on September 11, 2024.

Can I download this Lung Cancer Considered episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.